Restoring hope, building trust, and improving quality of life through readily available and safe transfusion solutions.
Secure Transfusion Solutions (STS) aims to increase the quality, safety, and availability of transfusable blood components, especially apheresis platelets. We give institutions—large and small—the peace of mind of knowing that they’ll receive a consistent and reliable supplemental source of platelets. Customers of STS include some of the most well-respected and innovative medical institutions in the country. By partnering with STS, hospital systems strengthen their supply chain and are better prepared to meet the transfusion needs of their patients.
Leaders in science and service
Board of Directors
Laurence Cooper, MD, PhD
Cell and gene therapy inventor and entrepreneur
Founder & CEO, Secure Transfusion Solutions, Inc.
SVP of Regulatory & Quality, Cerus Corporation
George “Bud” Scholl
CEO, OneBlood, Inc.
Andrew Heaton, MBBS
Former Chief Medical Officer, Novartis Diagnostics
William (Bill) Mercer
Former Executive, Terumo BCT
John Roback, MD, PhD
Department of Pathology & Laboratory Medicine,
Emory University School of Medicine
Susan Shurin, MD
Former Deputy Director of National Heart, Lung, and Blood Institute
Cutting-edge partners help us deliver cutting-edge solutions
Through our strategic partnerships, STS can deliver pathogen-reduced platelets to help hospitals and their patients around the US.
A commitment to quality
Your patients’ safety and your institution’s reputation are our top priority. STS is a member of both the AABB and the Plasma Protein Therapeutics Association (PPTA).